AC
PTLA

Avestar Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Avestar Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-431
Closed -$11K – 954
2019
Q2 		$11K Hold
431
– – 0.01% 493
2019
Q1 		$14K Buy
+431
New +$12.4K 0.01% 430

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Avestar Capital's PTLA Position: Q3 2019 in Review

Avestar Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2019, closing a stake of 431 shares — an estimated $11K sold.

Avestar Capital first reported a position in PTLA in Q1 2019 and held it in 2 quarters. The position peaked at $14K in Q1 2019. 212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

  • Avestar Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 431 Portola Pharmaceuticals, Inc. shares in Q3 2019, an estimated $11K.
  • Avestar Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Avestar Capital's Portola Pharmaceuticals, Inc. position peaked at $14K in Q1 2019.
  • 212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.